Intravitreal Bevacizumab for Macular Edema from Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis.

To assess the potential visual benefit of intravitreal bevacizumab in a patient with macular edema from idiopathic retinal vasculitis, aneurysms, and neuroretinitis, an intravitreal injection of bevacizumab (1.25 mg) was given. Within 1 week, visual acuity improved from 20/60 to 20/30 and optical coherence tomography demonstrated resolution of macular edema. There was no adverse effect. The macular edema returned after 3 months, and a repeat treatment of bevacizumab led to resolution of macular edema once again. An intravitreal injection of bevacizumab may provide potential short-term visual benefit in patients with macular edema from idiopathic retinal vasculitis, aneurysms, and neuroretinitis.